Patents Assigned to Merck
  • Publication number: 20220040184
    Abstract: In its many embodiments, the present invention provides certain substituted amino triazolopyrimidine and amino triazolopyrazine compounds of Formula (IA) and Formula (IB): and, and pharmaceutically acceptable salts thereof, wherein, R1, n, R2, and R3 are as defined herein, pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other therapeutically active agents), and methods for their preparation and use, alone and in combination with other therapeutic agents, as antagonists of A2a and/or A2b receptors, and their use in the treatment of a variety of diseases, conditions, or disorders that are mediated, at least in part, by the adenosine A2a receptor and/or the adenosine A2b receptor.
    Type: Application
    Filed: November 15, 2019
    Publication date: February 10, 2022
    Applicant: Merck Sharp Dohme Corp.
    Inventors: Zachary G. Brill, Amjad Ali, Jared Cumming, Duane DeMong, Qiaolin Deng, Gioconda V. Gallo-Etienne, Thomas H. Graham, Rongze Kuang, Matthew A. Larsen, Yeon-Hee Lim, Kun Liu, Umar Faruk Mansoor, Jesus Moreno, Brandon A. Vara, Huijun Wang, Yonglian Zhang
  • Publication number: 20220040917
    Abstract: The present invention is directed to a process for the preparation of a coated solid pharmaceutical dosage form using 3D printing technology.
    Type: Application
    Filed: September 12, 2019
    Publication date: February 10, 2022
    Applicant: MERCK PATENT GMBH
    Inventors: Malte BOGDAHN, Stefan SCHILLER, Andrea HANEFELD, Simon GEISSLER
  • Patent number: 11245079
    Abstract: The invention relates to compounds which are suitable for use in electronic devices, and electronic devices, in particular organic electroluminescent devices, containing said compounds.
    Type: Grant
    Filed: April 22, 2019
    Date of Patent: February 8, 2022
    Assignee: MERCK PATENT GMBH
    Inventors: Anja Jatsch, Tobias Grossmann, Amir Hossain Parham, Thomas Eberle, Christof Pflumm, Jonas Kroeber, Philipp Stoessel, Elvira Montenegro, Rouven Linge
  • Publication number: 20220033496
    Abstract: The present invention provides antibodies and antigen-binding fragments thereof that bind to ILT4 (immunoglobulin-like transcript 4) and combinations thereof, e.g., with an anti-PD1 antibody. Also provided are methods of use thereof, for example, for treating or preventing cancer in a subject; and methods of making such antibodies and fragments.
    Type: Application
    Filed: June 3, 2021
    Publication date: February 3, 2022
    Applicants: Merck Sharp & Dohme Corp., Agenus Inc.
    Inventors: Milan BLANUSA, Barbara JOYCE-SHAIKH, Andrea Claudia SCHUSTER, Kornelia SCHULTZE, Luis A. ZUNIGA
  • Publication number: 20220033711
    Abstract: The invention relates to a polymerisable LC material comprising one or more di- or multireactive mesogenic compounds and one or more compounds of formula UVI, wherein the individual radicals have one of the meaning as given in the claims. Furthermore, the present invention relates also to a method for its preparation, a polymer film with improved thermal durability and UV stability obtainable from a corresponding polymerisable LC material, to a method of preparation of such polymer film, and to the use of such polymer film and said polymerisable LC material for optical, electro-optical, decorative or security devices.
    Type: Application
    Filed: November 29, 2019
    Publication date: February 3, 2022
    Applicant: MERCK PATENT GMBH
    Inventors: Yong-Hyun CHOI, Jae-Hyun KANG, Hyun-Jin YOON
  • Publication number: 20220034902
    Abstract: A method is described for identifying high affinity monoclonal antibody heavy and light chain pairs from high throughput screens of antibody producing cell libraries such as B-cell and hybridoma libraries. Specifically, the method relates to application of reversed immunocapture and high resolution tandem mass spectrometry for the identification of heavy and light chain pairs of binding antibodies obtained from high throughput screens of antibody producing cell libraries.
    Type: Application
    Filed: December 6, 2019
    Publication date: February 3, 2022
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Eberhard Durr, Yaping Liu, Zhifeng Chen, Arthur Fridman
  • Publication number: 20220033435
    Abstract: A class of polycyclic compounds of general formula (I), wherein Base1, Base2, Y, Ya, Xa, Xa1, Xb, Xb1, Xc, Xc1, Xd, Xd1, R1, R1a, R2, R2a, R3a, R4, R5, R5a, R6, R6a, R7, R7a, R8, R8a, and R9 are defined herein, that may be useful as inductors of type I interferon production, specifically as STING active agents, are provided. Also provided are processes for the synthesis and use of compounds (I).
    Type: Application
    Filed: December 2, 2019
    Publication date: February 3, 2022
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Michael D. Altman, Wonsuk Chang, Jared N. Cumming, Hong Liu, Benjamin Wesley Trotter
  • Publication number: 20220031837
    Abstract: The present invention provides pneumococcal conjugate vaccine formulations comprising surfactant systems incorporating polysorbate 20 or a combination of a poloxamer and a polyol.
    Type: Application
    Filed: August 26, 2021
    Publication date: February 3, 2022
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: William J. Smith, Cecilia Giovarelli, Denise K. Nawrocki
  • Publication number: 20220033431
    Abstract: A class of polycyclic compounds of general formula (I), wherein Base1, Base2, Y, Ya, Xa, Xa1, Xb, Xb1, Xc, Xc1, Xd, Xd1, R1, R1a, R2a, R3, R3a, R4, R4a, R5, R6, R6a, R7, R7a, R8, R8a, and R9 are defined herein, that may be useful as inductors of type I interferon production, specifically as STING active agents, are provided. Also provided are processes for the synthesis and use of compounds.
    Type: Application
    Filed: December 2, 2019
    Publication date: February 3, 2022
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Michael D. Altman, Wonsuk Chang, Jared N. Cumming, Hong Liu, Benjamin Wesley Trotter
  • Publication number: 20220033845
    Abstract: The invention provides expression vectors for expressing recombinant proteins (e.g., biologics) in mammalian cells. Also provided are host cells comprising the expression vectors, methods of producing the recombinant proteins, and methods of propagating the expression vectors.
    Type: Application
    Filed: September 23, 2019
    Publication date: February 3, 2022
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Zhimei Du, Bo Jiang, Xiaoyan Tang
  • Publication number: 20220033497
    Abstract: Humanized, non-promiscuous monoclonal antibodies specific for immunoglobulin-like transcript 3 (ILT3), also known as Leukocyte immunoglobulin-like receptor subfamily B member 4 (LILRB4), are described.
    Type: Application
    Filed: July 16, 2021
    Publication date: February 3, 2022
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Michael A. Meehl, Philip E. Brandish, Laurence Fayadat-Dilman, Veronica Juan, Carl Mieczkowski, Latika Singh
  • Patent number: 11236063
    Abstract: Compounds of the formula I in which groups and parameters that occur have the definitions given in the disclosure. Preparation methods for these compounds. Uses of the compounds as components in liquid-crystalline media. Electrooptical display elements comprising the liquid-crystalline media.
    Type: Grant
    Filed: June 11, 2018
    Date of Patent: February 1, 2022
    Assignee: MERCK PATENT GMBH
    Inventors: Lars Lietzau, Achim Goetz, Harald Hirschmann, Martin Engel
  • Patent number: 11236271
    Abstract: The present invention relates to liquid crystalline (LC) medium, to a method of its production and to the use of such LC media in polymer network liquid crystalline (PNLC) light modulation elements operated in the normally transparent mode. Furthermore, the present invention relates to such light modulation elements, as such, to the use of such light modulation elements as light shutters for transparent OLED displays, to the use of such light modulation elements in smart windows, and to a method of production of such light modulation elements according to the present invention.
    Type: Grant
    Filed: September 4, 2017
    Date of Patent: February 1, 2022
    Assignee: Merck Patent GmbH
    Inventors: Dong-Mee Song, Hyun-Woo Bae, Jung-Min Lee, Yong-Kuk Yun
  • Patent number: 11235063
    Abstract: A heterodimeric bispecific immunoglobulin molecule includes a first Fab or scFv fragment which specifically binds to EGFR, and a second Fab or scFv fragment which specifically binds to c-MET, and an antibody hinge region, an antibody CH2 domain and an antibody CH3 domain including a hybrid protein-protein interaction interface domain. Each of the interaction interface domains is formed by an amino acid segment of the CH3 domain of a first member and an amino acid segment of the CH3 domain of a second member. The hybrid protein-protein interface domain of the first chain is interacting with the protein-protein-interface of the second chain by homodimerization of a corresponding amino acid segment of the same member of the immunoglobulin superfamily within interaction domains.
    Type: Grant
    Filed: October 27, 2016
    Date of Patent: February 1, 2022
    Assignee: Merck Patent GmbH
    Inventors: Achim Doerner, Lars Toleikis, Vanita D. Sood, Carolin Sellmann, Christine Knuehl
  • Patent number: 11234914
    Abstract: The present invention relates to the use of monosubstiuted urea derivatives of the formula I as self-tanning substance, for increasing melanin synthesis, for improving melanin transport and/or improving the distribution of melanin in suprabasal layers, and to preparations comprising these urea derivatives.
    Type: Grant
    Filed: October 2, 2017
    Date of Patent: February 1, 2022
    Assignee: MERCK PATENT GMBH
    Inventors: Julian Osthoff, Hansjuergen Driller, Christophe Carola, Robin Back, Michael Krohn
  • Publication number: 20220026414
    Abstract: A functional cell-based assay for use as a bioidentity assay for insulin or insulin analogs is described. The assay may be used as a replacement of the rabbit blood sugar method disclosed in USP<121> Insulin Assays.
    Type: Application
    Filed: December 6, 2019
    Publication date: January 27, 2022
    Applicant: Merck Sharp & Dohme Corp.
    Inventor: Junming Yie
  • Publication number: 20220025043
    Abstract: Humanized, non-promiscuous monoclonal antibodies specific for immunoglobulin-like transcript 3 (ILT3), also known as Leukocyte immunoglobulin-like receptor subfamily B member 4 (LILRB4), are described.
    Type: Application
    Filed: July 16, 2021
    Publication date: January 27, 2022
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Michael A. Meehl, Philip E. Brandish, Laurence Fayadat-Dilman, Veronica Juan, Carl Mieczkowski, Latika Singh
  • Publication number: 20220024940
    Abstract: The present invention is directed towards the hemisulfate salt of 5,10-methylene-(6R)-tetrahydrofolic acid, preferably in substantially crystalline form, as well as pharmaceutical compositions and uses thereof in therapy, preferably chemotherapy.
    Type: Application
    Filed: October 8, 2021
    Publication date: January 27, 2022
    Applicant: MERCK & CIE
    Inventors: Rudolf MOSER, Viola GROEHN, Thomas EGGER, Thomas AMMANN
  • Publication number: 20220025265
    Abstract: A liquid-crystalline media having a negative dielectric anisotropy and a high clearing point as specified herein, is suitable for use of in switchable optical cells in window elements, in particular laminated window elements.
    Type: Application
    Filed: July 15, 2021
    Publication date: January 27, 2022
    Applicant: Merck Patent GmbH
    Inventors: Hoo-Yong LEE, Hyun-Jin YOON
  • Patent number: D942268
    Type: Grant
    Filed: April 29, 2021
    Date of Patent: February 1, 2022
    Assignee: Merck KGaA
    Inventors: Mark Hinkle, Jeffrey Whitford